Zoetis
✦ Quant Fair Value how this is computed
- Implied fair-value range of 133.55-254.04, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -59.2% below the average-multiple fair value of 193.80.
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
| Viatris (VTRS) | 22.50B | -37.04 | 1.64 | 2.45% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 22.6% below Morningstar's fair value estimate.
Analyst note
Zoetis reported third-quarter results that included operational revenue falling 1% to $2.39 billion and adjusted diluted EPS up 3% to $1.75. Both exceeded FactSet consensus estimates, however, shares closed down 8% Nov. 5, likely reflecting management's hints of caution for 2027.
Why it matters: Now that Zoetis is facing direct, energized competition for the first time in over a decade, the question has been whether the firm can play defense as well as it has long played offense. This quarter has given a peek at Zoetis' substantial efforts to fend off competition. There's never been any question that Zoetis would cede dermatology share in the face of new competition. But, the firm is tapping the brakes on share loss with targeted promotion and a chewable formulation. Apoquel lost 7 points of share in the second quarter but reined it in to a 4-point decline in the third quarter. The Simparica Trio parasiticide fared even better and maintained share leadership at 23% globally, supported strongly by international markets upgrading to the triple-combination product.
The bottom line: We've raised our fair value estimate to $97 per share, from $86, as this quarter's results suggest our earlier view is too pessimistic and underestimates the firm's ability to slow share loss between now and when it expects to roll out new products with blockbuster potential. Wide-moat Zoetis has also been able to preserve gross margin better than we'd expected for 2026 (at nearly 72% year to date). We still anticipate further gross margin pressure in 2027 but now believe it will be less severe than before—bottoming out at 69% rather than 67% previously. As we look to 2027 and 2028, we expect the launch of long-acting Cytopoint and especially a novel therapy for canine renal disease to become key growth drivers. We think the latter could eventually peak at $1 billion considering the mortality related to kidney disease in dogs.
Finally, Librela continues to see declines in the US on safety concerns. Now that long-acting Lenivia is expected to receive US Food and Drug Administration approval next year, Zoetis could see its osteoarthritis monoclonal antibody portfolio return to mild growth in the US. Thus far, Lenivia has seen favorable reception where it is approved in Europe and Canada. We note that Lenivia relies on a different mechanism of action than Librela, and thus, its safety profile could also be different. Nonetheless, Librela also saw enthusiastic adoption outside the US, and any safety issues only emerged after the drug was launched in the US later. While we're not predicting the same pattern with Lenivia, we think US dog owners may be cautious about Lenivia.
Fair value
We've raised our fair value estimate to $97 per share, from $86, as third-quarter results suggest our earlier view is too pessimistic and underestimates the firm's ability to slow share loss. We continue to project a 3% decline companion animal revenue for 2027, before assuming gradual recovery in segment growth from innovative products starting in 2028. We still assume that Zoetis permanently cedes substantial market share in dermatology and triple-combination parasiticides through 2030. In the midterm, though, we anticipate the firm will introduce novel canine therapies for kidney failure and cancer—two undertreated markets that Zoetis would pioneer—along with long-acting Cytopoint and a long-acting canine parasiticide, thereby supporting a return to mid-single-digit growth in the companion animal business by 2030. This translates into consolidated average annual revenue growth of roughly 1% through 2030.
We continue to expect the production animal segment growth to generally normalize in the low single digits through our explicit forecast period, influenced substantially by ongoing drought conditions that have affected cattle herd sizes. It's possible for a disease outbreak to accelerate production animal growth, though these usually offer one-time benefits before the outbreak dissipates.
We also adjusted our earlier our profitability projections, considering the firm's recent ability to preserve profitability better than we'd expected. Following management's acknowledgment that Zoetis is taking price actions to fend off competition and defend market share in dermatology and parasiticides, we still think the firm will see gross margin take a hit in the near term before novel products are launched. We now assume gross margin bottoms out in 2027 at 69%—down approximately 250 basis points from 2025—rather than at 67%. Upon the introduction of several novel therapies with blockbuster potential starting in 2028, we project gross margin to improve to 71% by 2030.
Finally, we maintain our estimate for long-term earnings power at 5%, reflecting the increasingly crowded competitive field for dermatology and parasticides.
Economic moat
Zoetis enjoys a wide Morningstar Economic Moat Rating thanks to its significant intangible assets. Similar to human pharma companies, Zoetis benefits from patents that allow it to charge a premium price and insulate it from competition. Currently, Zoetis owns over 5,880 patents, with another 1,500 pending. This is roughly 900 more than at freestanding rival Elanco. Further, as with other pharma firms, Zoetis relies heavily on composition of matter patents, which offer particularly strong protection.
Most recently, Zoetis has reached commercial success with several monoclonal antibodies for companion animal use. As with other biologic therapies, replicating Cytopoint, Lenivia and Solensia will likely be challenging for competitors after patents expire. We anticipate Zoetis will maintain its leadership position in monoclonal antibodies and extend its presence on this platform into additional therapeutic areas (for example, cardiac, renal, and oncology).
Zoetis enjoys another intangible asset in the form of strong brand names on specific products. We think this is a particularly significant dynamic in companion animal products, where consumer familiarity and veterinarian recommendation play a role. When customers are using drugs on a pet that is, for all intents and purposes, another family member, they are willing to pay a premium to buy the brand that their vet trusts and that they think has worked well for their pet. We’ve seen this pet owner preference manifest in a very long tail after the patent on Rimadyl (nonsteroidal anti-inflammatory for arthritis) expired 30 years ago.
Zoetis also enjoys another intangible asset, in comparison with its competitors that are embedded in larger human pharmaceutical firms: It is free to develop therapeutics based on unmet animal needs. For most competitors, application of therapeutics originally designed for humans to the animal market also means those firms are unlikely to invest in animal-specific therapies. There are some sizable opportunities related to unmet animal needs that Zoetis can pioneer, including Cytopoint for canine allergies.
In terms of environmental, social, and governance issues, Morningstar Sustainalytics rates Zoetis as low risk. Considering the probability and materiality of the key risks, we do not see much risk of an ESG matter permanently impairing Zoetis' moat. From our perspective, most of the risk lies with product governance. There is the risk of potentially defective products harming pets, though we doubt this leaves the firm vulnerable to much in the way of legal liability, given the lifespan and market value of dogs and cats.
There is also the possibility that medications ingested by production animals make their way into the human food supply. This issue has taken on a higher profile recently thanks to more evidence of rising antibiotic resistance and concerns about milk containing growth hormone given to dairy cows to increase production. We've seen much of the immediate risk dissipate through a combination of greater regulatory scrutiny, industrywide decisions to respond to consumer concerns, and management’s decision to divest some of its medicated feed products. This has translated into a reduction in Zoetis' exposure to this risk.
Finally, we think there is a longer-term risk in the form of more consumers embracing vegetarian/vegan diets or reducing the volume of meat consumed in the interest of mitigating the environmental impact of raising production animals. This is especially true in the industrial farm model. There is also the potential commercialization of lab-grown meat, which could reduce demand for production animal therapeutics. Nonetheless, we view these risks as long-term issues that are unlikely to disrupt Zoetis' business unexpectedly, and we anticipate an ongoing mix shift toward the companion animal division, which should also offer some insulation from production animal challenges.
Bull case
Growing interest in probiotics, antibacterial peptides, and immune modulators as alternatives to antibiotics offers many targets for innovation.
Companion animals are increasingly viewed as family members, drastically increasing owners' willingness to spend on pet healthcare.
Because the animal health industry lacks large payers like Medicare, single-payer governments, or large insurance companies, Zoetis maintains significant pricing power.
Bear case
Strict regulation or restriction of antibiotic use in animals could harm Zoetis' sales of production animal products.
New safety data might not assuage pet owner concerns about Librela in the US, which might lead to further declines through 2026.
Recessionary conditions and financial stress could pressure pet health spending and pet adoption or even increase pet surrenders.
By Debbie S. Wang
Quote time 2026-11-20 19:41:38 · For reference only, not investment advice and not tailored to your situation.
Zoetis discussion 0 comments